ASSESSMENT During the tachyarrhythmia, the patient had a blood pressure of 85/64 mm Hg. He was alert, oriented, and not in acute distress. A cardiopulmonary examination was negative for decompensated heart failure or valvular disease. He was given 6-mg and 12-mg doses of adenosine intravenously without success. Next, amiodarone, 150 mg, was given intravenously without results. Ultimately, sinus rhythm was achieved ( Figure 1B) with 100 joules of external electrical cardioversion.
A transthoracic echocardiogram demonstrated a normal left ventricular ejection fraction of 55-60% and no significant valvular abnormalities. Serial cardiac biomarkers were negative. Coronary angiography did not demonstrate any significant coronary artery disease.
DIAGNOSIS
The patient then underwent an electrophysiology study. With invasive mapping techniques, the tachyarrhythmia focus was found to originate in the left posterior fascicle, confirming that the patient's tachyarrhythmia was consistent with fascicular ventricular tachycardia.
The presentation of wide complex tachycardia can pose a diagnostic dilemma for the clinician, with significant differences in choice of treatment depending on the etiology of the arrhythmia. Most wide complex tachycardias are the result of ischemic heart disease and should be identified and treated according to current guidelines on pharmacologic and therapeutic interventions. 1, 2 The differential diagnosis for these arrhythmias also may include supraventricular tachycardia with aberrancy and idiopathic ventricular tachycardia.
Fascicular ventricular tachycardia represents a less common subgroup of these idiopathic ventricular tachycardias. It can be misdiagnosed easily and over-treated with antiarrhythmic drugs and cardioversion in the acute setting, because it is relatively infrequent. This fairly benign rhythm, which originates near and involves 1 of the 2 fascicles of the left ventricular conduction system, occurs in individuals without any evidence of ischemic or structural heart disease. Typically, fascicular ventricular tachycardia is found in young, otherwise healthy individuals at a mean age of 31 years (range, 12-68 years of age) who have a chief complaint of palpitations. [3] [4] [5] Belhassen et al first identified that these arrhythmias could be effectively terminated and/or suppressed with verapamil. 6 In addition to the patient's clinical presentation, fascicular ventricular tachycardia can be identified from its characteristic ECG findings ( Table 1) . Left posterior fascicular ventricular tachycardia, occurring in up to 90% of cases, has a QRS complex that resembles a right bundle branch block (RBBB) morphology with left axis deviation, consistent with left anterior fascicular block. In approximately 10% of cases, fascicular ventricular tachycardia arises from the left anterior fascicle and has a QRS complex with a RBBB morphology and right-axis deviation due to concurrent left posterior fascicular block. Rarely, the origin is in the left upper septum, and the ECG shows a narrow QRS configuration and normal or right-axis deviation (< 1% of cases). 8 Fascicular ventricular tachycardia is believed to result from a macroreentry circuit involving the Purkinje system near the left posterior fascicle that is triggered by an abnormal slow pathway with verapamil sensitivity. 8, 10 Because the reentry circuit does not involve the atrioventricular node; administration of adenosine has no effect. 11, 12 On a cellular level, fascicular ventricular tachycardia appears to be primarily dependent on slow inward calcium channels in the Purkinje system. 13 MANAGEMENT Verapamil is effective in slowing and terminating episodes of fascicular ventricular tachycardia, and it remains the pharmacologic treatment of choice. Adenosine, lidocaine, and propranolol can be ineffective and should not be used if fascicular ventricular tachycardia is suspected. 5, 11 Calcium channel blockers have been suggested as first-line treatment for any hemodynamically stable patient without underlying ischemic heart disease who presents with broad complex tachycardia and RBBB. 14 Still, caution should be exercised in patients-especially in older patients-who present with an unknown diagnosis, as calcium channel blockers are contraindicated in ischemiarelated ventricular tachycardia; deletrious hemodynamic effects can be provoked. 15 Cardiology consultation should be considered.
For long-term management of fascicular ventricular tachycardia, oral verapamil has been shown to be effective in mild to moderate cases, but it may be ineffective in patients with severe symptoms. 3, 16 For those intolerant of or noncompliant with oral therapy or who have refractory symptoms, catheter-based ablation has been found to be an effective and safe option. While there is concern for tachycardia-induced cardiomyopathy in severe cases, the overall long-term prognosis of fascicular ventricular tachycardia is excellent with a very low risk for lethal ventricular arrhythmias and/or sudden cardiac death. 16 The patient underwent successful radiofrequency ablation of the focus of the fascicular ventricular tachycardia, and was discharged on extended released diltiazem 120 mg daily. He has had no further recurrences. 
